Weei-Chin Lin

Weei-Chin Lin, M.D., Ph.D.

Dan L. Duncan Endowed Professor

Email

weeichil@bcm.edu

Positions

Dan L. Duncan Endowed Professor: Medicine-Hematology & Oncology
��logo
Houston, TX, US

Professor: Department of Molecular and Cellular Biology
��logo
Houston, Texas, United States

Dan L Duncan Endowed Professor: Dan L Duncan Comprehensive Cancer Center
��logo
Houston, Texas, United States

Co-Director: Cancer & Cell Biology Graduate Program
��logo

Faculty: Development, Disease Models & Therapeutics Graduate Program
��logo

Addresses

Alkek Building for Biomedical Research (Office): Room: ABBR-R410
Houston, TX, 77030
United States

Education

PhD from Johns Hopkins University School Of Medicine: 05/1993 - Baltimore, Maryland, United States

MD from National Taiwan University: 06/1986 - Taipei, Taiwan, Taiwan

Post-Doctoral Fellowship at Johns Hopkins University School of Medicine: 06/1994 - Baltimore, Maryland, United States

Residency at Duke University Medical Center: 06/1996 - Durham, North Carolina, United States

Clinical Fellowship at Duke University Medical Center: 06/1999 - Durham, North Carolina, United States

Certifications

Texas Medical Board

Diplomate, American Board of Internal Medicine

Subspecialty in Medical Oncology, ABIM

Subspecialty in Hematology, ABIM

Honors & Awards

Dan Duncan Professorship of Oncology: ��logo (01/2010)

The Leukemia & Lymphoma Society Scholar: (07/2006 - 06/2011)

General Motors Cancer Research Scholar: (01/2002 - 01/2005)

Howard Hughes Medical Institute Junior Faculty Development Award: (06/2001 - 06/2004)

Damon Runyon-Walter Winchell Physician Scientist Award: Duke University (04/1999 - 05/2001)

The Martin and Carol Macht Research Prize: Johns Hopkins University (05/1993)

Professional Interests

Cell cycle regulation
Development of cancer therapeutics
Clinical hematology

Professional Statement

I am a physician-scientist and maintain an active research program and clinical practice. My research focuses on defining mechanisms linking cell-cycle control, genome integrity, and cancer. My early studies discovered the cell-cycle regulation of RAG2 and V(D)J recombination, revealing a fundamental mechanism that coordinates cell-cycle progression with programmed DNA rearrangement and laying the foundation for subsequent insights into aberrant recombination and lymphomagenesis. My subsequent research has elucidated critical mechanisms of cell-cycle and DNA-damage regulation, including the roles of TopBP1, E2F1, mutant p53, and RNF144A in cancer. These discoveries have revealed key vulnerabilities underlying tumor development and therapeutic resistance. More recently, we have developed first-in-class inhibitors targeting the BRCT7/8 domains of TopBP1, translating our original discoveries in cancer biology into novel therapeutic strategies for therapy-resistant cancers.

Websites

news in research (new TopBP1 inhibitor overcomes drug resistance)

news in research (mutant p53 and immunotherapy)

Medicine/Hematology Oncology

Cancer & Cell Biology Graduate Program

Development, Disease Models & Therapeutics Graduate Program

Selected Publications

" ;
Fang-Tsyr Lin, Shwu-Jiuan Lin, Kang Liu , Yang Xiao, Lidija A Wilhelms Garan, Helena Folly-Kossi, Weei-Chin Lin. " " Sci Adv.. 2026 Aug 7; 7 (12(32)) : eaeg1996.
Pubmed PMID: .
Kang Liu, Lidija AW Garan, Fang-Tsyr Lin, Weei-Chin Lin. " " Communications Biology. 2025 ; 8(1) (1522)
Pubmed PMID: .
Fang-Tsyr Lin, Kang Liu, Lidija A Wilhelms Garan, Helena Folly-Kossi, Yongcheng Song, Shwu-Jiuan Lin, Weei-Chin Lin. " " Proc Natl Acad Sci U S A. 2023 Oct 25;
Pubmed PMID: .
Folly-Kossi H, Graves JD, Wilhelms Garan LA, Lin FT, Lin WC.. " " Cancer Res Commun.. 2023 Oct 16; 3 (10) : 2096-112.
Pubmed PMID: .
Lin WC, Lin FT. " " Proc Natl Acad Sci U S A.. 2022 Dec 5; 119 (50) : e2217953119.
Pubmed PMID: .
Garan LA, Xiao Y, Lin WC. " " Proc Natl Acad Sci U S A.. 2022 Oct 17; 119 (43) : e2209211119.
Pubmed PMID: .
Ho SR, Lee YC, Ittmann MM, Lin FT, Chan KS, Lin WC. " " Cancer Lett.. 2021 Aug 13; 520 (2021) : 344-360.
Pubmed PMID: .
Liu K, Graves JD, Lin FT, Lin WC. " " J Biol Chem. 2021 Feb 5; https://doi.org/10.1016/j.jbc.2021.100382
Pubmed PMID: .
Xiao Y, Lin FT, Lin WC. " " Proc Natl Acad Sci U S A. 2021 Jan 19; 118 (3) : 1-12.
Pubmed PMID: .
Graves JD, Lee YJ, Liu K, Li G, Lin FT, Lin WC. " " Proc Natl Acad Sci U S A. 2020 Jun 30; 117 (26) : 11958-14969.
Pubmed PMID: .
Liu K, Graves JD, Lee YJ, Lin FT, Lin WC. " " Mol Cell Biol. 2020 Mar 30; 40 (8) : 1-19.
Pubmed PMID: .
Lee YJ, Ho SR, Graves JD, Xiao Y, Huang S, Lin WC. " " Breast Cancer Res. 2019 Dec 4; 21 (1) : 1-22.
Pubmed PMID: .
Ho SR, Lin WC. " " J Biol Chem. 2018 Oct 19; 293 (42) : 16307-16323.
Pubmed PMID: .
Liu K, Lin FT, Graves JD, Lee YJ, and Lin WC.. " " Proc Natl Acad Sci U S A. 2017 Apr 24; doi: 10.1073/pnas.1619832114 (PNAS Early Edition) : 1-10.
Pubmed PMID: .
Mahanic CS, Budhavarapu V, Graves JD, Li G, Lin WC.. " " J Biol Chem. 2015 Oct 30; 290 (44) : 26508-22.
Pubmed PMID: .
Ho SR, Lee YJ, Lin WC.. " " J Biol Chem. 2015 Sep 18; 290 (38) : 23026-38.
Pubmed PMID: .
Chowdhury P, Lin GE, Liu K, Song Y, Lin FT, Lin WC. " " Nat Commun.. 2014 Nov 17; (5) : 5476.
Pubmed PMID: .
Ho SR, Mahanic CS, Lee YJ, Lin WC. " " Proc Natl Acad Sci U S A.. 2014 Jul 1; 111 (26) : E2646-55.
Pubmed PMID: .
Xiao Y, Lin VY, Ke S, Lin GE, Lin FT, Lin WC. " " Mol Cell Biol.. 2014 May 12; 34 (14) : 2635-49.
Pubmed PMID: .
Liu K, Graves JD, Scott JD, Li R, Lin WC. " " Mol Cell Biol.. 2013 Dec ; 33 (23) : 4685-700.
Pubmed PMID: .
Budhavarapu VN, White ED, Mahanic CS, Chen L, Lin FT, Lin WC. " " Cell Cycle. 2012 May 15; 11 (10) : 2030-8.
Pubmed PMID: .
Liu K, Ling S, Lin WC. " " Mol. Cell. Biol.. 2011 Nov ; 31 (22) : 4464-81.
Pubmed PMID: .
Ling S, Lin WC. " " J. Biol. Chem.. 2011 Apr 29; 286 (17) : 14972-82.
Pubmed PMID: .
Wang B, Liu K, Lin HY, Bellam N, Ling S, Lin WC. " " Mol. Cell. Biol.. 2010 Mar ; 30 (6) : 1508-27.
Pubmed PMID: .
Paik JC, Wang B, Liu K, Lue JK, Lin WC. " " J. Biol. Chem.. 2010 Feb 26; 285 (9) : 6348-63.
Pubmed PMID: .
Liu K, Bellam N, Lin HY, Wang B, Stockard CR, Grizzle WE, Lin WC. " " Mol. Cell. Biol.. 2009 May ; 29 (10) : 2673-93.
Pubmed PMID: .
Yang SZ, Lin FT, Lin WC. " " EMBO Rep.. 2008 Sep ; 9 (9) : 907-15.
Pubmed PMID: .
Liu K, Paik JC, Wang B, Lin FT, Lin WC. " " EMBO J.. 2006 Oct 18; 25 (20) : 4795-807.
Pubmed PMID: .
Luo Y, Lin FT, Lin WC. " " Mol. Cell. Biol.. 2004 Jul ; 24 (14) : 6430-44.
Pubmed PMID: .
Liu K, Luo Y, Lin FT, Lin WC. " " Genes Dev.. 2004 Mar 15; 18 (6) : 673-86.
Pubmed PMID: .
Liu K, Lin FT, Ruppert JM, Lin WC. " " Mol. Cell. Biol.. 2003 May ; 23 (9) : 3287-304.
Pubmed PMID: .
Lin WC, Lin FT, Nevins JR. " " Genes Dev. 2001 Jul 15; 15 (14) : 1833-44.
Pubmed PMID: .
Lin WC, Desiderio S. " " Immunol Today .. 1995 Jun 16; 16 (6) : 279-89.
Pubmed PMID: .
Lin WC, Desiderio S. " " Proc Natl Acad Sci U S A. 1994 Mar 29; 91 (7) : 2733-7.
Pubmed PMID: .
Lin WC, Desiderio S. " " Science. 1993 May 14; 260 (5110) : 953-9.
Pubmed PMID: .

Intellectual Property

: Method Patent #US 9,636,323 (Approved); Establishes TopBP1 as a therapeutic target and provides treatment strategies for TopBP1-overexpressing cancers.; Co Inventors: Weei-Chin Lin, Pinki Chowdhury, Gregory E. Lin, Kang Liu, Yongcheng Song, Fang-Tsyr Lin

: Product Patent #PCT/US24/48843 (Pending); Novel compounds that suppress MYC signaling and enhance the activity of PARP-targeted therapies.; Co Inventors: Weei-Chin Lin, Fang-Tsyr Lin

: Product Patent #64/125,660 (Pending); Novel TopBP1-BRCT7/8 inhibitors and their therapeutic applications in cancer treatment.; Co Inventors: Weei-Chin Lin, Fang-Tsyr Lin

to edit your profile

����logo